[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Observation
February 9, 2004

Human Immunodeficiency Virus–Associated NephropathyA Primary Care Perspective

Author Affiliations

From the Divisions of General Medicine (Dr Olatinwo), Infectious Diseases (Dr Hewitt), Nephrology (Dr Venuto), and School of Medicine, State University of New York, Buffalo, and the Immunodeficiency Service, Erie County Medical Center, Buffalo (Drs Olatinwo and Hewitt). The authors have no relevant financial interest in this article.

Arch Intern Med. 2004;164(3):333-336. doi:10.1001/archinte.164.3.333
Abstract

The advent of highly active antiretroviral therapy represents a significant advance in medical care for human immunodeficiency virus (HIV)-infected persons. However, not everyone has derived the expected benefits of antiretroviral therapy and HIV-associated diseases such as nephropathy still occur in at-risk populations. Currently, there are no recommendations for screening HIV-positive patients for HIV-associated nephropathy. We propose semiannual screening for proteinuria in HIV-positive African Americans and patients with a family history of renal disease, and provide an algorithm for evaluation.

×